Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Apr-24 5:17 PM View:  | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 801 | $17.90 | $14,337.90 | (< 1%) 126.83K to 126.02K | |
| 08-Apr-24 5:18 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 3,932 | -- | -- | 21% 19.06K to 22.99K | |
| 08-Apr-24 5:20 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 2,694 | -- | -- | 16% 16.87K to 19.56K | |
| 08-Apr-24 5:19 PM View: | Moat Ross Chief Commercial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 2,477 | -- | -- | 16% 15.15K to 17.63K | |
| 08-Apr-24 5:21 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 2,497 | -- | -- | 5% 46.04K to 48.54K | |
| 08-Apr-24 5:18 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 1,666 | $17.90 | $29,821.40 | (7%) 22.99K to 21.33K | |
| 08-Apr-24 5:22 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 9,992 | -- | -- | 6% 166.89K to 176.88K | |
| 08-Apr-24 5:20 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 791 | $17.90 | $14,158.90 | (4%) 19.56K to 18.77K | |
| 08-Apr-24 5:19 PM View: | Moat Ross Chief Commercial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 1,353 | $17.90 | $24,218.70 | (8%) 17.63K to 16.28K | |
| 08-Apr-24 5:21 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 733 | $17.90 | $13,120.70 | (2%) 48.54K to 47.8K | |
| 08-Apr-24 5:22 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Payment of Exercise | 4,075 | $17.90 | $72,942.50 | (2%) 176.88K to 172.81K | |
| 08-Apr-24 5:17 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 08-Apr-24 | Option Exercise | 2,726 | -- | -- | 2% 124.1K to 126.83K | |
| 03-Apr-24 5:21 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 1,084 | $19.70 | $21,354.80 | (5%) 20.15K to 19.06K | |
| 03-Apr-24 5:22 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 6,482 | -- | -- | 4% 162.31K to 168.79K | |
| 03-Apr-24 5:25 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 514 | $19.70 | $10,125.80 | (3%) 17.38K to 16.87K | |
| 03-Apr-24 5:20 PM View: | Moat Ross Chief Commercial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 880 | $19.70 | $17,336.00 | (5%) 16.03K to 15.15K | |
| 03-Apr-24 5:18 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 477 | $19.70 | $9,396.90 | (1%) 46.52K to 46.04K | |
| 03-Apr-24 5:22 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 1,903 | $19.70 | $37,489.10 | (1%) 168.79K to 166.89K | |
| 03-Apr-24 5:23 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 1,773 | -- | -- | 1% 122.85K to 124.62K | |
| 03-Apr-24 5:23 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Payment of Exercise | 521 | $19.70 | $10,263.70 | (< 1%) 124.62K to 124.1K | |
| 03-Apr-24 5:21 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 2,558 | -- | -- | 15% 17.59K to 20.15K | |
| 03-Apr-24 5:25 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 1,750 | -- | -- | 11% 15.63K to 17.38K | |
| 03-Apr-24 5:20 PM View: | Moat Ross Chief Commercial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 1,612 | -- | -- | 11% 14.42K to 16.03K | |
| 03-Apr-24 5:18 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Apr-24 | Option Exercise | 1,624 | -- | -- | 4% 44.89K to 46.52K | |
| 11-Mar-24 7:05 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 07-Mar-24 | Private Sale (Planned) | 65,012 | $21.02 | $1,366,550.00 | (29%) 227.32K to 162.31K | |
| 06-Mar-24 10:00 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 06-Mar-24 | Sale (Planned) | 5,582 | $21.00 | $117,222.00 | (2%) 232.91K to 227.32K | |
| 06-Mar-24 10:00 PM View: | Patel Sanj K Chairman & CEO Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 04-Mar-24 | Private Sale (Planned) | 12,742 | $21.49 | $273,834.00 | (5%) 245.65K to 232.91K | |
| 05-Mar-24 4:31 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Option Exercise | 18,844 | $1.86 | $35,049.80 | 42% 44.89K to 63.74K | |
| 05-Mar-24 4:34 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Sale (Planned) | 533 | $22.03 | $11,742.00 | (< 1%) 123.38K to 122.85K | |
| 05-Mar-24 4:34 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Option Exercise | 656 | $1.59 | $1,043.04 | < 1% 123.38K to 124.04K | |
| 01-Mar-24 6:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Planned Option Sale | 9,659 | $21.45 | $207,186.00 | (35%) 27.25K to 17.59K | |
| 05-Mar-24 4:31 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Planned Option Sale | 18,844 | $21.77 | $410,234.00 | (30%) 63.74K to 44.89K | |
| 01-Mar-24 6:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Option Exercise | 9,659 | $10.93 | $105,560.00 | 55% 17.59K to 27.25K | |
| 05-Mar-24 4:34 PM View: | Tessari Eben Chief Operating Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 01-Mar-24 | Planned Option Sale | 656 | $22.03 | $14,451.70 | (< 1%) 124.04K to 123.38K | |
| 01-Mar-24 6:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 28-Feb-24 | Planned Option Sale | 5,126 | $21.79 | $111,696.00 | (23%) 22.71K to 17.59K | |
| 01-Mar-24 6:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 28-Feb-24 | Option Exercise | 5,126 | $8.83 | $45,262.60 | 29% 17.59K to 22.71K | |
| 29-Feb-24 4:26 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 27-Feb-24 | Planned Option Sale | 10,156 | $21.03 | $213,581.00 | (18%) 55.05K to 44.89K | |
| 29-Feb-24 4:26 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 27-Feb-24 | Option Exercise | 10,156 | $1.86 | $18,890.20 | 23% 44.89K to 55.05K | |
| 01-Mar-24 6:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 15-Jan-24 | Grant | 583 | $12.35 | $7,200.05 | 3% 17.0K to 17.59K | |
| 04-Jan-24 4:30 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 03-Jan-24 | Option Exercise | 12,000 | $8.83 | $105,960.00 | 77% 15.63K to 27.63K | |
| 04-Jan-24 4:30 PM View: | Ragosa Mark Chief Financial Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 03-Jan-24 | Planned Option Sale | 12,000 | $20.00 | $240,000.00 | (43%) 27.63K to 15.63K | |
| 04-Jan-24 4:30 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 02-Jan-24 | Option Exercise | 16,670 | $13.88 | $231,380.00 | 98% 17.0K to 33.67K | |
| 04-Jan-24 4:30 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 02-Jan-24 | Planned Option Sale | 16,670 | $19.17 | $319,564.00 | (50%) 33.67K to 17.0K | |
| 21-Dec-23 4:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 19-Dec-23 | Option Sale | 9,316 | $19.13 | $178,215.00 | (35%) 26.32K to 17.0K | |
| 21-Dec-23 4:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 19-Dec-23 | Option Exercise | 9,316 | $13.88 | $129,306.00 | 55% 17.0K to 26.32K | |
| 11-Dec-23 4:20 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 07-Dec-23 | Option Exercise | 28,600 | $1.86 | $53,196.00 | 64% 44.89K to 73.49K | |
| 11-Dec-23 4:20 PM View: | Paolini John Chief Medical Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 07-Dec-23 | Planned Option Sale | 28,600 | $17.65 | $504,758.00 | (39%) 73.49K to 44.89K | |
| 07-Nov-23 4:33 PM View: | Levy Richard S Director | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 03-Nov-23 | Option Exercise | 2,777 | -- | -- | 56% 5.0K to 7.78K | |
| 06-Oct-23 4:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 04-Oct-23 | Payment of Exercise | 52 | $16.01 | $832.52 | (< 1%) 17.06K to 17.0K | |
| 06-Oct-23 4:26 PM View: | Megna Michael R Chief Accounting Officer | Kiniksa Pharmaceuticals, Ltd. (KNSA) | 04-Oct-23 | Option Exercise | 175 | -- | -- | 1% 16.88K to 17.06K |
